Oragenics, Inc. (NYSE MKT:OGEN), a healthcare company focused on
becoming the world leader in novel antibiotics against infectious
disease and probiotcs for oral health, announced today that it will be
included in the Russell Microcap Index when Russell Investments
reconstitutes its comprehensive set of U.S. and global equity indexes on
Friday, June 28, 2013, according to a preliminary list of additions
posted June 21st on www.russell.com/indexes.
Dr. John N. Bonfiglio, Chief Executive Officer of Oragenics, said, “On
the heels of listing on NYSE MKT in May, we see the addition to the
Russell Microcap Index as a reflection of Oragenics’ positive momentum.
The inclusion in the index marks another milestone for the Company as we
garner greater investor awareness for our lantibiotics and oral
probiotics business segments.”
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. Russell calculates more than 700,000 benchmarks
daily covering approximately 98 percent of the investable market
globally, 80 countries and more than 10,000 securities. Approximately
$4.1 trillion in assets are benchmarked to the Russell Indexes.
Annual reconstitution of Russell Indexes captures the 4,000 largest U.S.
stocks as of the end of May, ranking them by total market capitalization
to create the Russell 3000® Index and Russell Microcap Index. These
investment tools originated from Russell's multi-manager investment
business in the early 1980s when the company saw the need for a more
objective, market-driven set of benchmarks in order to evaluate outside
investment managers. Membership in the Russell Microcap Index, which
remains in place for one year, means automatic inclusion in the
appropriate growth and value style indexes. Russell determines
membership for its equity indexes primarily by objective,
market-capitalization rankings and style attributes
Total returns data for the Russell Microcap and other Russell Indexes is
available at http://www.russell.com/indexes/data/US_Equity/Russell_US_Index_returns.asp.
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel
antibiotics against infectious disease and probiotics for oral health
for humans and pets. Oragenics has established an exclusive worldwide
channel collaboration for lantibiotics, a novel class of broad spectrum
antibiotics, with Intrexon Corporation Inc., a synthetic biology
company. The collaboration will allow Oragenics access to Intrexon's
proprietary technologies with the idea of accelerating the development
of much needed new antibiotics that will work against resistant strains
of bacteria. Oragenics also develops, markets and sells proprietary
probiotics specifically designed to enhance oral health for humans and
pets, under the brand names Evora
and ProBiora
in over 13 countries worldwide.
For more information about Oragenics, visit www.oragenics.com.
Follow Oragenics on Facebook
and Twitter.
Safe Harbor Statement: Under the Private Securities
Litigation Reform Act of 1995: This release includes forward-looking
statements that reflect the Company’s current views with respect to
future events and financial performance. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “project” and similar expressions
that do not relate solely to historical matters identify forward-looking
statements. Investors should be cautious in relying on forward-looking
statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to
differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to our ability to
raise additional capital to sustain our operations beyond March 31, 2014
and those set forth in our most recently filed annual report on Form
10-K and quarterly report on Form 10-Q, and other factors detailed from
time to time in filings with the U.S. Securities and Exchange
Commission. We expressly disclaim any responsibility to update
forward-looking statements.
Copyright Business Wire 2013